150 related articles for article (PubMed ID: 7500009)
1. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
Skorski T; Nieborowska-Skorska M; Campbell K; Iozzo RV; Zon G; Darzynkiewicz Z; Calabretta B
J Exp Med; 1995 Dec; 182(6):1645-53. PubMed ID: 7500009
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
[TBL] [Abstract][Full Text] [Related]
5. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
6. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
[TBL] [Abstract][Full Text] [Related]
7. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
Skorski T; Nieborowska-Skorska M; Barletta C; Malaguarnera L; Szcyzlik C; Chen ST; Lange B; Calabretta B
J Clin Invest; 1993 Jul; 92(1):194-202. PubMed ID: 8325984
[TBL] [Abstract][Full Text] [Related]
8. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
Nieborowska-Skórska M; Nakashima M; Ratajczak M; Steplewski Z; Calabretta B; Skórski T
Folia Histochem Cytobiol; 1994; 32(1):35-40. PubMed ID: 8026602
[TBL] [Abstract][Full Text] [Related]
9. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
Szczylik C; Skorski T; Nicolaides NC; Manzella L; Malaguarnera L; Venturelli D; Gewirtz AM; Calabretta B
Science; 1991 Aug; 253(5019):562-5. PubMed ID: 1857987
[TBL] [Abstract][Full Text] [Related]
11. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Skórski T; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Gewirtz AM
Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
[TBL] [Abstract][Full Text] [Related]
14. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.
Skorski T; Kanakaraj P; Ku DH; Nieborowska-Skorska M; Canaani E; Zon G; Perussia B; Calabretta B
J Exp Med; 1994 Jun; 179(6):1855-65. PubMed ID: 8195713
[TBL] [Abstract][Full Text] [Related]
15. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
[TBL] [Abstract][Full Text] [Related]
16. Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice.
Honda H; Fujii T; Takatoku M; Mano H; Witte ON; Yazaki Y; Hirai H
Blood; 1995 May; 85(10):2853-61. PubMed ID: 7537982
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
[TBL] [Abstract][Full Text] [Related]
18. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
19. The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo.
Nieborowska-Skórska M; Białek AP; Nicolaides NC; Iozzo RV; Kawalec M; Calabretta B; Kawiak J; Marlicz K; Skórski T
Folia Histochem Cytobiol; 1996; 34(2):69-73. PubMed ID: 8875213
[TBL] [Abstract][Full Text] [Related]
20. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
